

# THE LANCET

## Supplementary appendix

This appendix formed part of the original submission. We post it as supplied by the authors.

Supplement to: Østergaard SD, Schmidt M, Horváth-Puhó E, Thomsen RW, Sørensen HT. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? *Lancet* 2021; published online March 30. [http://dx.doi.org/10.1016/S0140-6736\(21\)00762-5](http://dx.doi.org/10.1016/S0140-6736(21)00762-5).

**Table: Study population size, number of venous thromboembolisms, follow-up time and incidence rate of venous thromboembolism in Denmark.**

*A. Any venous thromboembolism (VTE)*

Population	Number of individuals	Number of VTE	Total follow-up time (years)	Incidence-rate / 1000 person years (95%CI)
<b>18–99 year old</b>				
Total	4,915,426	67,746	38,449,703	1.76 (1.75–1.78)
Female	2,486,428	34,320	19,523,245	1.76 (1.74–1.78)
Male	2,428,998	33,426	18,926,446	1.77 (1.75–1.79)
<b>18–64 year old</b>				
Total	3,963,153	28,134	29,537,310	0.95 (0.94–0.96)
Female	1,960,197	13,205	14,656,397	0.90 (0.89–0.92)
Male	2,002,956	14,929	14,880,913	1.00 (0.99–1.02)

*B. Deep vein thrombosis or pulmonary embolism (DVT/PE)*

Population	Number of individuals	Number of DVT/PE	Total follow-up time (years)	Incidence-rate / 1000 person years (95% CI)
<b>18–99 year old</b>				
Total	4,917,080	65,267	38,468,076	1.70 (1.68–1.71)
Female	2,487,331	33,158	19,533,127	1.70 (1.68–1.72)
Male	2,429,749	32,109	18,934,949	1.70 (1.68–1.71)
<b>18–64 year old</b>				
Total	3,964,227	26,750	29,549,108	0.91 (0.89–0.92)
Female	1,960,781	12,545	14,662,777	0.86 (0.84–0.87)
Male	2,003,446	14,205	14,886,330	0.95 (0.94–0.97)

**Example of the estimation of venous thromboembolism (VTE) incidence in 5 million people**

1.76 VTE / 1000 person years = 1.76 VTE / 365,250 person-days = 0.00000482 VTE / day. 0.00000482 VTE / day × 7 days = 0.00003373 VTE / week. 0.00003373 VTE / week × 5,000,000 persons = 169 VTE / week

**Author contributions**

All authors contributed to the study design. EHP carried out the data analysis. EHP and HTS verified the underlying data. All authors contributed to the data interpretation. SDØ wrote the first draft of the manuscript, which was subsequently revised for important intellectual content by the remaining authors. All authors approved the final version of the manuscript prior to submission.

**Funding**

There was no direct funding of this study. Østergaard reports funding from the Lundbeck Foundation (grant numbers: R358-2020-2341 and R344-2020-1073), the Novo Nordisk Foundation (grant number: NNF20SA0062874), the Danish Cancer Society (grant number: R283-A16461), the Central Denmark Region Fund for Strengthening of Health Science (grant number: 1-36-72-4-20), The Danish Agency for Digitisation Investment Fund for New Technologies (grant number 2020-6720), and Independent Research Fund Denmark (grant number: 7016-00048B). Schmidt reports funding from the Novo Nordisk Foundation (grant NNF19OC0054908). These funding bodies were not involved in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.